Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 2002

View Archived Issues

Sangamo and Medarex establish collaboration for antibody production

FDA advisory committee delays review of Bexxar

Validated target selected by Aventis in osteoarthritis research collaboration with GPC Biotech

Lundbeck gains exclusive marketing rights to Keppra in Canada

Synthetic selectin antagonist OJ-R9188 may be useful in Rx of atopic dermatitis

Combination therapy with WelChol and statin may reduce LDL to NCEP recommended target levels

GenVec to develop AIDS vaccines under agreement with the NIH

Patent coverage obtained by NeoPharm for a NeoLipid antisense compound

Ceplene plus IL-2 prolongs survival in subset of metastatic melanoma patients

Several aspects of the echinocandin antifungal agent FK-463 reported at ICAAC

Chiron obtains option to Procyon prostate cancer technology

Biotica receives Marie Curie Fellowship grant

Interim analysis of first phase III Provenge trial inconclusive

IND for satraplatin transferred to NeoOncoRx

Novo Nordisk terminates development agreement with Flamel for Basulin

NanoCarrier and GSK to carry out feasibility studies to deliver GSK compound

High-dose HspE7 effective and well tolerated in high-grade anal dysplasia

Endotoxin-induced fibrinolysis specifically blocked by anti-CD14 antibody in humans

Oncolytic viruses from Cell Genesys show potential in combination therapy of tumors

New sialoadhesin factor-3 antibodies prepared at GSK

Neuroprotective and antiproliferative compounds identified at Aegera

Fujisawa presents new serotonergic agents and their use

Glycine transporter inhibitors useful for cognition disorders according to Yamanouchi and Merck

Lilly patents piperidylindoles which are ligands for 5-HT receptors

Merck patents two series of NK1 receptor antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...